Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 485

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 485
---
 losses are included in earnings and are derived using the specific identification method for determining the cost of investments sold. The Company classifies short-term investments with remaining maturities greater
than one year as current assets because such short-term investments are available to fund the Company’s current operations.

At each balance sheet
date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the decline in fair value below amortized cost is a result
of credit losses or other factors, whether the Company expects to recover the amortized cost of the security, the Company’s intent to sell and if it is more likely than not that the Company will be required to sell the securities before the
recovery of amortized cost. The Company records changes in allowance for expected credit loss in other income (expense). There has been no allowance for expected credit losses recorded during any of the periods presented. See Note 4 for further
information.

Accounts Receivable, Net

Accounts receivable are recorded net of customer allowances for chargebacks and allowance for credit losses. Allowance for chargebacks is based on contractual
terms. The Company estimates the allowance for credit losses based on existing contractual payment terms, actual payment patterns of its individual customer circumstances and credit loss. Receivables are recorded to an allowance for credit loss when
it is probable that amounts will not be collected based on terms of the customer contracts. Accounts receivable are net of $0.2 million and $0.1 million of customer allowances for chargebacks as of December 31, 2023 and
December 31, 2022, respectively. There were no allowances for credit losses and no receivables were written off for the years ended December 31, 2023 and 2022.

Inventory

Inventory is stated at the lower of
cost or estimated net realizable value. The Company uses actual costing methodology determined on a first-in, first-out method. The Company capitalizes inventory costs
associated with its products based upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed.

F-12

Details of inventory are presented as follows (in thousands):

|                 |     | As of December 31, |  2023 |     |   |  2022 |
|:----------------|:----|:-------------------|------:|:----|:--|------:|
| Raw materials   |     | $